Search Results
Your search for ,New matches 16916 pages
Showing 3401 - 3450Durability of Responses to BCMA CAR T-Cell Therapy in Patients With Multiple Myeloma May Depend on Specific Components of the Tumor Microenvironment
Currently, there are two U.S. Food and Drug Administration–approved chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) for adult patients with relapsed or refractory multiple myeloma: idecabtagene vicleucel and citacabtagene autoleucel. However, although ...
New Cervicovaginal Epigenetic Test for Screening of Suspected Endometrial Cancer
As reported in the Journal of Clinical Oncology, Herzog et al have developed a simple noninvasive test for screening for suspected endometrial cancer—the Women’s Cancer Risk Identification-Quantitative Polymerase Chain Reaction Test for Endometrial Cancer (WID-qEC)—that has shown accuracy in...
ASTRO Issues Clinical Guideline on Radiation Therapy for IDH-Mutant Glioma
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma. Evidence-based recommendations outline the multidisciplinary...
Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs...
FDA Approves Cabozantinib for Patients With Previously Treated Radioactive Iodine–Refractory Differentiated Thyroid Cancer
On September 17, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for the treatment of adult and pediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth...
Thyroidectomy With or Without Radioiodine for Low-Risk Thyroid Cancer
In the French phase III ESTIMABL2 trial reported in The New England Journal of Medicine, Leboulleux et al found that no use of radioiodine was noninferior to radioiodine ablation in the occurrence of functional, structural, or biologic events among patients undergoing thyroidectomy for low-risk...
HPV Vaccination and Projected Oropharyngeal Cancer Incidence Through the Year 2045
In a population-based age-period-cohort study reported in JAMA Oncology, Zhang et al estimated that current human papillomavirus (HPV) vaccination rates will have a limited impact on overall oropharyngeal cancer incidence through 2045, due to a high risk of oropharyngeal cancer in unvaccinated...
Prevalence of MGUS Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster
In an observational seroprevalence study reported in Blood Cancer Journal, Zeig-Owens et al found an elevated prevalence of myeloma precursor disease—monoclonal gammopathy of undetermined significance (MGUS)—in a cohort of World Trade Center (WTC) disaster–exposed rescue and recovery workers....
Head and Neck Cancer 2021–2022 Almanac
Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...
Study Shows AI May Improve Prediction of Colorectal Cancer Recurrence
In a multinational study using artificial intelligence (AI), investigators developed an algorithm to improve the prediction of colorectal cancer recurrence. Study results were published by Pai et al in Gastroenterology. QuantCRC Rish K. Pai, MD, PhD, a pathologist at Mayo Clinic in Arizona and...
Researchers Outline a Path to Representation in Cancer Clinical Trials
A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...
FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement
On August 26, the U.S. Food and Drug Administration (FDA) approved pemigatinib (Pemazyre), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. Myeloid/lymphoid neoplasms with...
Researchers Identify Markers of Chemotherapy Resistance and Outcome in Patients With Triple-Negative Breast Cancer
Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...
Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy
In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...
Success Story in Prostate Cancer for Many Men
“I now think of prostate cancer as a story of success for many men, given the advancements in both research and treatment options over the past decade,” Behfar Ehdaie, MD, MPH, told The ASCO Post. Dr. Ehdaie is lead author of a study that found MRI-guided focused ultrasound focal therapy is safe...
MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer
MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...
Surviving Advanced Prostate Cancer Has Made Me a More Empathetic Physician
My diagnosis of terminal prostate cancer 3 years ago was filled with irony. As an interventional radiologist, I have treated hundreds of patients with advanced prostate cancer, and I knew my prognosis wasn’t good. After experiencing some of the common symptoms of the cancer, including voiding...
Dong Quai
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the herb dong...
The Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine Appoints New Directors
Jedd Wolchok, MD, PhD, FASCO, an internationally acclaimed medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment, has been chosen as the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Dr. Wolchok played a pivotal role...
FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica) for pediatric patients aged at least 1 year with chronic graft-vs-host disease after failure of one or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension. iMAGINE Trial...
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...
Elotuzumab Plus Pomalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: ELOQUENT-3 Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the phase II ELOQUENT-3 trial showed significant benefit with the addition of elotuzumab to pomalidomide and dexamethasone (EPd) vs pomalidomide and dexamethasone...
Anna Sureda, MD, PhD, on Large B-Cell Lymphoma: New Data on Axicabtagene Ciloleucel vs Standard of Care
Anna Sureda, MD, PhD, of the University of Barcelona and the Catalan Institute of Oncology, discusses phase III clinical and patient-reported outcomes from the ZUMA-7 trial, which showed that axicabtagene ciloleucel was superior to second-line standard-of-care treatment in patients 65 years or...
Harry P. Erba, MD, PhD, on AML: New Data on Quizartinib Plus Standard Chemotherapy
Harry P. Erba, MD, PhD, of Duke Cancer Institute, discusses potentially practice-changing phase III results from the QuANTUM-First trial, which showed that adding quizartinib to standard chemotherapy and up to 3 years of continuation therapy led to improvement in overall survival for adults aged 18 ...
Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia
Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...
Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer
For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...
Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot
ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...
2023 Hospital Outpatient Payment Proposal Does Not Reflect SCOTUS Ruling on 340B Reimbursement
On July 15, 2022, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2023 Medicare Hospital Outpatient Prospective Payment System (OPPS). ASCO is assessing the full proposal, but ASCO’s initial analysis is as follows. In June 2022, the Supreme Court ruled that ...
New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations
Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...
Biden Administration Announces New Model to Improve Cancer Care for Medicare Patients
On June 27, 2022, the Biden Administration, through the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS), announced a new model aimed at improving cancer care for Medicare patients and lowering health-care costs. CMS’ Center for Medicare...
Racial Trends in Advanced Cervical Cancer in the United States
The steepest annual rise in new cases of advanced cervical cancer in the United States from 2001 to 2018 was among White patients, who were significantly less likely to receive the preventive human papillomavirus (HPV) vaccine or to be screened for the disease, according to research published by...
APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years
Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...
Snapshots of Studies of Interest Presented at ASCO 2022
The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...
Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer
As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...
Is Science Getting Closer to Preventing Multiple Myeloma?
About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...
Epcoritamab Under Study in Difficult-to-Treat Large B-Cell Lymphoma
Subcutaneous epcoritamab, a bispecific antibody, has demonstrated deep and durable responses in a large expansion cohort of patients with relapsed or refractory large B-cell lymphoma (LBCL), according to late-breaking data presented during the European Hematology Association (EHA) 2022 Congress in...
Is Advance Care Planning of Any Value?
An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...
Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?
Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...
T-DXd Shows High Intracranial Response Rate in Patients With Active Brain Metastases From HER2-Positive Breast Cancer
In the investigator-initiated, prospective, open-label, single-arm phase II TUXEDO-1 study conducted among patients with newly diagnosed or progressive brain metastases from HER2-positive breast cancer, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) yielded responses according...
First-Line Lenalidomide/Rituximab vs Rituximab/Chemotherapy With Rituximab Maintenance for Advanced Follicular Lymphoma
As reported in the Journal of Clinical Oncology by Franck Morschhauser, MD, PhD, and colleagues, 6-year results from the second interim analysis of the phase III RELEVANCE trial show similar progression-free and overall survival with lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-chemo)...
Expert Point of View: Michael Cecchini, MD
The ASCO Post asked Michael Cecchini, MD, Assistant Professor of Medicine and Co-Director of the Colorectal Program in the Center for Gastrointestinal Cancer at Yale School of Medicine and Smilow Cancer Hospital Center, New Haven, to comment on the RATIONALE-306 findings. He said the study...
Study Reveals Potential Genomic Contributors to the Development of DLBCL
By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...
WBI With Boost After Breast-Conserving Surgery in Non–Low-Risk DCIS
As reported in The Lancet by Chua et al, the phase III BIG 3-07/TROG 07.01 trial has shown reduced risk of local recurrence with vs without tumor bed boost after conventional or hypofractionated whole-breast irradiation (WBI) in women receiving breast-conserving surgery for non–low-risk ductal...
A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...
Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers
A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...
Molecular Map Reveals Insights Into the Genetic Drivers of CLL
A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy, which could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were...
Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL
Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...
Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer
Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...
Characteristics of Data Supporting FDA Initial Approval and Subsequent Indications for New Cancer Drugs
In a study reported in the Journal of Clinical Oncology, Michaeli and Michaeli described data supporting U.S. Food and Drug Administration (FDA) initial approval and subsequent indications for new cancer drugs from 2003 through 2021. Study Details Clinical trial evidence supporting approval for...
Study Finds AYA Leukemia Survivors Have Higher 10-Year Mortality Rates Than the General Population
Although considered a rare occurrence in adolescents and young adults (AYAs), aged 15 to 39 years, the incidence of cancer in this age group has been increasing by approximately 30% since the 1970s. This year, it is estimated that nearly 90,000 new cases of cancer will be diagnosed in this...
